A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
Clinical trial NCT02545075 · COMPLETED
Trial details
- NCT number
- NCT02545075
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-10-31
- Primary completion
- 2019-04-19
- Enrollment
- 182
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.